Motixafortide alone and in combination with natalizumab can support the collection of the large number of stem cells required ...

Sickle cell disease causes excruciating pain and damage to the body. But now there are new treatments that can put an end to ...

Most people with sickle cell disease who undergo allogeneic hematopoietic cell transplantation achieve favorable long-term ...

Scientific American hosted an event at Morehouse School of Medicine to highlight medical advances in treating sickle cell ...

Adding erythropoietin to hydroxyurea treatment could significantly improve quality of life for patients with sickle cell ...

Iron overload is prevalent among adults with sickle cell disease (SCD), according to a study presented at the annual meeting ...

Patients who underwent hematopoietic cell transplantation for sickle cell disease saw high rates of survival without disease ...

Cellarity, a clinical-stage biotechnology company developing Cell State-Correcting therapies through integrated multi-omics and AI modeling, today announced the presentation of new preclinical data on ...

Iron overload is prevalent among adults with sickle cell disease (SCD), according to a study presented at the annual meeting ...

Patients who underwent hematopoietic cell transplantation for sickle cell disease saw high rates of survival without disease ...

Key Highlights Motixafortide effectively mobilized sufficient hematopoietic stem cells (HSCs) in patients with sickle cell disease enabling accelerated access to gene therapies 90% (9 of 10) of ...

Only 1 in 3 patients in an ER for sickle cell crisis receive opioid painkillers within the first hour as treatment guidelines ...